Inspire Medical Systems (STU:2DR) 3-Year RORE % : 81.28% (As of Mar. 2026)


STU:2DR Inspire Medical Systems Inc STU:2DR
59 GF Score
Price €45.40
GF Value €186.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Inspire Medical Systems 3-Year RORE %?

Inspire Medical Systems STU:2DR +1.79% 59 3-Year RORE % is 81.28 as of Mar. 2026. GuruFocus rates STU:2DR with a GF Score™ of 59/100 and a GF Value™ of €186.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 777 Medical Devices & Instruments companies, Inspire Medical Systems ranks better than 89.96% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Inspire Medical Systems's 3-Year RORE % for the quarter that ended in Mar. 2026 was 81.28%.

The industry rank for Inspire Medical Systems's 3-Year RORE % or its related term are showing as below:

STU:2DR's 3-Year RORE % is ranked better than
89.96% of 777 companies
in the Medical Devices & Instruments industry
Industry Median: -4.03 vs STU:2DR: 81.28

Inspire Medical Systems  (STU:2DR) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Inspire Medical Systems 3-Year RORE % Related Terms


Inspire Medical Systems 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Inspire Medical Systems's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inspire Medical Systems 3-Year RORE % Chart

Inspire Medical Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.36 -7.90 -17.07 -498.44 95.54

Inspire Medical Systems Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58,933.33 747.39 186.84 95.54 81.28

STU:2DR vs ENOV, PRCT, AHCO: 3-Year RORE % Comparison

For the Medical Devices subindustry, Inspire Medical Systems's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inspire Medical Systems 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Inspire Medical Systems's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Inspire Medical Systems's 3-Year RORE % falls into.


STU:2DR
59GF Score
Inspire Medical Systems Inc STU:2DR
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inspire Medical Systems 3-Year RORE % Calculation

Inspire Medical Systems's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 3.829--0.514 )/( 5.343-0 )
=4.343/5.343
=81.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 81.28 mean?
Inspire Medical Systems (STU:2DR) has a 3-Year RORE % of 81.28 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Inspire Medical Systems and its competitors. According to the industry distribution chart, Inspire Medical Systems ranks #78 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 10%.
Is Inspire Medical Systems' 3-Year RORE % too high?
Inspire Medical Systems' current 3-Year RORE % is 81.28. Based on the distribution chart, Inspire Medical Systems ranks #78 out of 777 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Inspire Medical Systems has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Inspire Medical Systems' 3-Year RORE % compare to ENOV and PRCT?
According to the Medical Devices & Instruments industry distribution chart, Inspire Medical Systems ranks #78 out of 777 companies for 3-Year RORE %. This places Inspire Medical Systems in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Inspire Medical Systems and its competitors. Inspire Medical Systems's current 3-Year RORE % is 81.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inspire Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Inspire Medical Systems (STU:2DR) is currently considered Possible Value Trap. The stock's GF Value™ is €186.29, compared to a current price of €45.40 — trading 75.6% below its estimated fair value. The current 3-Year RORE % is 81.28. Inspire Medical Systems' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Inspire Medical Systems (STU:2DR), the current 3-Year RORE % is 81.28 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Inspire Medical Systems (STU:2DR) Overvalued in 2026?

Based on GuruFocus' analysis, Inspire Medical Systems stock appears to be undervalued. The current stock price of €45.40 is trading 75.6% below its estimated GF Value™ of €186.29. GuruFocus considers Inspire Medical Systems to be Possible Value Trap.

Key valuation signals for STU:2DR:

  • 3-Year RORE %: 81.28
  • GF Value™: €186.29 vs. price of €45.40 (75.6% below fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the STU:2DR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Inspire Medical Systems Business Description

Other Exchanges INSP:USA
Address 5500 Wayzata Boulevard, Suite 1600, Golden Valley, MN, USA, 55416
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
59GF Score

Get the complete analysis for STU:2DR

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€45.40
Price
€186.29
GF Value